Traumatic brain injury (TBI) is a significant health problem and a potentially catastrophic debilitating medical emergency with a poor prognosis and the possibility of long-term disability. Blast-related and closed-head injuries constitute the majority of TBIs occurring in the combat zone. Recent studies demonstrate that diffuse axonal injury (DAI) is the most common pathologic feature largely accounting for the clinical manifestations of TBI. Thus, future advancements in the diagnosis and treatment of TBI depend on our understanding of temporal axonal pathophysiology of DAI and its role in patient outcome. However, several factors have limited our understanding of the pathology and functional implications of DAI: (1) DAI is extremely difficult to detect noninvasively;(2) it develops over a course of hours to days, even months, after injury;(3) DAI is difficult to study because it involves multiple types of neurons and is diffuse and multifocal, appearing throughout the deep and subcortical white matter. This research project will take advantage of the optic nerve system to explore the hypothesis that an innovative neuroprotective and regenerative approach is effective on minimizing axonal damage and improving the morphological and functional recovery after CNS trauma. The optic nerve, which conveys visual information from the eye to brain, contains axons originated from a single neuronal population- retinal ganglion cells. Its peripheral location makes it an unusually accessible both structurally and functionally. Optic nerve injury that creates axonal damage morphologically identical to that seen in the brain offers a well-defined anatomical system that obviates many of the difficulties associated with experiments on the brain. Moreover, using the advanced mouse genetic technology, successful full-length optic nerve regeneration from the eye to the brain has been achieved in postnatal mice. The study demonstrates the feasibility of limiting DAI following TBI and treating brain trauma. To elucidate the pathology and mechanisms associated with axonal damage, especially DAI resulted from blast force-induced TBI (bTBI), and to develop new treatment, this research plan proposes 3 specific aims:
Aim 1 is proposed to define the pathology and mechanisms of axonal damage induced by trauma and/or TBI.
Aim 2 will use advanced mouse genetic technology to elucidate the molecular signals leading to the chronic axonal damage.
Aim 3 will evaluate a novel neuroprotective and regenerative approach to minimize axonal damage resulted from trauma. Quantification of neuron and axon damage will be carried out using the standard protocols of immunohistochemistry and molecular and biochemical assays that have been well-established. If the hypothesis is proven valid, an innovative technology that has strong implications for translation into clinical practice could be developed in the near future.
Civilians and military personnel working in or near combat zones are at risk for traumatic brain injury (TBI). Blast-related and closed-head injuries, rather than penetrating injuries, constitute the majority of TBIs in this population, and diffuse axonal injury is thought to be a major contributor to the neurocognitive deficits associated with TBI. However, the mechanisms responsible for the induction of neuronal consequences, chronic headaches and mood disorders, especially for those associated with blast-force induced TBI, are poorly understood. Through the proposed studies, we expect to better understand the pathology and mechanisms underlying neuron and nerve fiber damage after TBI and test the efficacy of a novel drug therapy for minimizing neuronal and axon damage associated with TBI. If successful, an innovative technology that has strong implications for translation into clinical practice will be developed. It may thus allow us to quickly move forward a pharmacological manipulation that can improve the outcome and facilitate functional recovery to the clinical stage for TBI therapy.
|Guo, Chenying; Cho, Kin-Sang; Li, Yingqian et al. (2018) IGFBPL1 Regulates Axon Growth through IGF-1-mediated Signaling Cascades. Sci Rep 8:2054|
|Yan, Naihong; Cheng, Lin; Cho, Kinsang et al. (2016) Postnatal onset of retinal degeneration by loss of embryonic Ezh2 repression of Six1. Sci Rep 6:33887|
|Fang, Yuan; Cho, Kin-Sang; Tchedre, Kissaou et al. (2013) Ephrin-A3 suppresses Wnt signaling to control retinal stem cell potency. Stem Cells 31:349-59|
|Yang, Qiang; Cho, Kin-Sang; Chen, Huihui et al. (2012) Microbead-induced ocular hypertensive mouse model for screening and testing of aqueous production suppressants for glaucoma. Invest Ophthalmol Vis Sci 53:3733-41|
|Rao, Rajesh C; Hennig, Anne K; Malik, Muhammad T A et al. (2011) Epigenetic regulation of retinal development and disease. J Ocul Biol Dis Infor 4:121-36|
|Wei, Xin; Yu, Zhanyang; Cho, Kin-Sang et al. (2011) Neuroglobin is an endogenous neuroprotectant for retinal ganglion cells against glaucomatous damage. Am J Pathol 179:2788-97|